STOCK TITAN

Roche Holding AG - RHHBY STOCK NEWS

Welcome to our dedicated news page for Roche Holding (Ticker: RHHBY), a resource for investors and traders seeking the latest updates and insights on Roche Holding.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Roche Holding's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Roche Holding's position in the market.

Rhea-AI Summary
Roche announces new data for OCREVUS in multiple sclerosis at ECTRIMS-ACTRIMS Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.08%
Tags
none
-
Rhea-AI Summary
Roche announces positive late-breaking data on OCREVUS subcutaneous injection for multiple sclerosis treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
none
-
Rhea-AI Summary
Genentech announces positive results from Phase IV CHIMES trial evaluating Ocrevus in Black and Hispanic/Latinx people with relapsing MS
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
clinical trial
Rhea-AI Summary
Roche announces positive long-term results for Vabysmo in retinal vein occlusion
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
clinical trial
-
Rhea-AI Summary
Genentech announces positive long-term results for Vabysmo in macular edema due to retinal vein occlusion
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
clinical trial
-
Rhea-AI Summary
Roche presents positive results from RAINBOWFISH study on Evrysdi treatment for babies with pre-symptomatic SMA, meeting primary endpoint with 80% of babies sitting without support for at least five seconds after 1 year of treatment. All babies were able to swallow and feed orally. Evrysdi is the only non-invasive SMA therapy approved in over 100 countries with more than 11,000 patients treated globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
none
Rhea-AI Summary
Positive results from the RAINBOWFISH study show that 80% of babies treated with Evrysdi were able to sit without support for at least 5 seconds after 1 year of treatment. Evrysdi is the only non-invasive SMA therapy and is approved in over 100 countries with more than 11,000 patients treated globally. The study also showed that all babies were able to swallow and feed orally, and none required permanent ventilation. Cognitive skills typical of normal child development were observed after 1 year of treatment. Adverse events were not considered treatment-related and there were no deaths or withdrawals. Early treatment for SMA before symptoms appear is valuable in preserving motor neurons.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
none
-
Rhea-AI Summary
Roche will present new data for OCREVUS and fenebrutinib for multiple sclerosis (MS) and ENSPRYNG for neuromyelitis optica spectrum disorder (NMOSD) at the 9th Joint ECTRIMS-ACTRIMS Meeting. OCREVUS shows significant benefit in slowing long-term disability progression and consistent long-term safety profile in MS. Real-world and clinical data demonstrate impact for underrepresented populations. Safety outcomes from more than 6,000 patients across 12 OCREVUS trials support its favorable safety profile over 10 years. ENSPRYNG shows promising results in NMOSD with lower infection rates compared to other treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
conferences
-
Rhea-AI Summary
Genentech will present new data for Ocrevus and fenebrutinib for multiple sclerosis (MS) and Enspryng for neuromyelitis optica spectrum disorder (NMOSD) at the 9th Joint ECTRIMS-ACTRIMS Meeting. Ocrevus shows significant benefit in slowing long-term disability progression and has a consistent safety profile. Real-world and clinical data demonstrate the impact of Ocrevus in underrepresented populations. Enspryng shows long-term safety and efficacy in NMOSD. Fenebrutinib demonstrates brain penetration and reduction of new lesion activity in MS.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
conferences
Rhea-AI Summary
Roche and Alnylam's Phase 2 study of zilebesiran meets primary endpoint with a greater than 15 mmHg reduction in systolic blood pressure at three months
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
clinical trial
Roche Holding AG

OTC:RHHBY

RHHBY Rankings

RHHBY Stock Data

205.51B
727.48M
0.16%
Medicinal and Botanical Manufacturing
Manufacturing
Link
Switzerland
Basel